Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024).

Authors: George Shenouda, Roberto Diaz, Bassam Abdulkarim, Kevin Petrecca, Scott Peter Owen, Valerie Panet-Raymond, Amro Mohammad, Miguel Barrera, William Davalan, Antoneta Baciu, Tationa Carvalho, Melissa Charbonneau, Marianna Perna, Tanya Kozel, Jeffery Hall, Marie-christine Guiot, Luis Souhami

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.2064

Source: Full article

---

Abstract

2064